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Tumour resistance to chemotherapy involving methylating agents such as DTIC (dacarbazine) and temozolomide is linked to
expression of the DNA repair protein O
6-alkylguanine-DNA alkyltransferase (MGMT). There is considerable interest in improving the
efficacy of such O
6-alkylating chemotherapy by the prior inactivation of MGMT. We have examined the effect of the modified guanine
base, O
6-(4-bromothenyl)guanine (PaTrin-2, Patrint, Lomeguatrib) on MGMT activity and cell or xenograft tumour growth inhibition
by temozolomide in the human breast carcinosarcoma cell line, MCF-7. PaTrin-2 effectively inactivated MGMT in MCF-7 cells (IC50
B6n M) and in xenografts there was complete inactivation of MGMT within 2h of dosing (20mgkg
 1 i.p.) and only slight recovery by
24h. MGMT inactivation in a range of murine host tissues varied between complete and B60%, with extensive recovery by 24h.
PaTrin-2 (10mM) substantially increased the growth inhibitory effects of temozolomide in MCF-7 cells (D60¼10mM with PaTrin-2 vs
400mM without). In MCF-7 xenografts, neither temozolomide (100mgkg
 1day
 1 for 5 days) nor PaTrin-2 (20mgkg
 1day
 1 for 5
days) had any significant effect on tumour growth. In contrast, the PaTrin-2–temozolomide combination produced a substantial
tumour growth delay: median tumour quintupling time was increase by 22 days (Po0.005) without any significant increase in toxicity
as assessed from animal weight. A PaTrin-2–temozolomide combination may therefore be beneficial in the treatment of human
breast cancers.
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Standard first-line chemotherapy for advanced breast cancer
results in disease regression in the majority of patients, but these
responses are rarely complete or sustained (Clemons et al, 1997).
There is, therefore, a continuing need to develop new treatments
and one potential strategy is the biochemical modulation of
tumour drug resistance.
The chemotherapeutic methylating (e.g. dimethyltriazenoimida-
zole-4-carboxamide (DTIC)) and chloroethylating (e.g. bischlor-
oethylnitrosourea (BCNU)) agents are well established in oncology
and are a component of high-dose therapy regimens used in the
treatment of breast cancer (Peters et al, 1994; Antman, 2001;
Bengala et al, 2001). These agents are cytotoxic principally by
virtue of their ability to alkylate DNA at the O
6 position of guanine,
and there is now considerable evidence that the DNA repair
protein O
6-alkylguanine-DNA alkyltransferase (MGMT) plays a
key role in determining tumour resistance to these drugs
(Margison and Santiba ´n ˜ez Koref, 2002; Gerson, 2002, 2004).
MGMT repairs alkylation at the O
6 position on guanine by
accepting the alkyl group onto a cysteine residue in its active site
in a stoichiometric and autoinactivating reaction. Cellular
resistance in vitro and in vivo is correlated with elevated MGMT
expression, and can be achieved in previously susceptible cell lines
and organisms by transfer and expression of cDNAs or genes
encoding MGMT. Furthermore, inactivation of MGMT, or gene
deletion in mice, renders resistant cells and tissues sensitive to O
6-
alkylating agents (Pegg, 1990; Margison et al, 2002, 2003; Margison
and Santiba ´n ˜ez Koref, 2002; Gerson, 2002, 2004).
Attempts to exploit this clinically have used methylating agents
to deplete MGMT, via the formation of O
6-methylguanine (O
6-meG)
in DNA, prior to the administration of a chloroethylating drug (e.g.
Clemons et al, 2003). These have been hampered by the similar
toxicities of the two agents, and no useful increase in therapeutic
index has been demonstrated (Micetich et al, 1992; Lee et al, 1993;
Smith et al, 1996; Hammond et al, 2004). Because of this, interest
has turned to inactivation of MGMT using inherently nontoxic
pseudosubstrates for the protein, such as O
6-benzylguanine (O
6-
BeG; reviewed in Pegg et al, 1995; Dolan and Pegg, 1997) and O
6-
(4-bromothenyl)guanine (PaTrin-2, Lomeguatrib; McElhinney
et al, 1998; Middleton et al, 2002; Middleton and Margison, 2003).
Temozolomide has recently been tested in breast cancer patients
using a 5-day regimen and was found to be ineffective (NCIC,
2001). In order to establish if this resistance can be reversed in
model systems, we have used the human breast adenocarcinoma
cell line, MCF-7, that, like many of the breast tumours we have
examined, expresses very high levels of MGMT. We show that
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sPaTrin-2 inactivates MGMT in cells and xenografts and that this
results in substantial increases in their sensitivity to growth
inhibition by temozolomide.
MATERIALS AND METHODS
Drugs
PaTrin-2 and temozolomide were provided by the Cancer Research
Campaign Drug Formulation Unit, University of Strathclyde,
Glasgow, UK. For cell culture studies, a stock solution of PaTrin-
2 (20mM) was prepared in dimethylsulphoxide (DMSO; Sigma,
Poole, Dorset, UK) and diluted into culture medium just prior to
use. For animal studies, PaTrin-2 was ground to a fine powder and
suspended in corn oil at 4mgml
 1 immediately prior to intra-
peritoneal (i.p.) injection. Temozolomide was freshly prepared at
40mgml
 1 in 20% DMSO/80% phosphate-buffered saline (PBS)
and diluted in 0.9% NaCl solution.
Cell culture studies
MCF-7 cells (a human breast adenocarcinoma cell line) were
grown as a monolayer in RPMI medium containing 10% foetal
bovine serum (Gibco BRL, Paisley, Scotland), at 371Ci na
humidified atmosphere of 5% CO2/95% air.
To determine MGMT inactivation, cells (5 10
6) were incubated
in the presence of increasing concentrations of PaTrin-2 at 371C,
5% CO2. After 2h, cells were pelleted and resuspended in 10ml
PBS. This was repeated three times in order to remove any residual
PaTrin-2. Finally, cells were pelleted and assayed for MGMT
activity as previously described (Watson and Margison, 2000).
Activity remaining, based on at least three points on the linear part
of the protein-dependence curve, was calculated as a percentage of
the activity in untreated cells.
To determine toxicity, the MTT [30 (4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide] growth inhibition assay, based
on the method of Carmichael et al (1987) was employed. Cells
(1000 per well) were plated into a 96-well plate and following a 24h
attachment period, PaTrin-2 was added to the cells. After 2h
incubation with PaTrin-2 (10mM)a t3 7 1C, 5% CO2, increasing
doses of temozolomide or vehicle were added and the cells were
incubated for a further 4–5 days. At the end of the exposure
period, 150mg MTT was added to each well and plates were
incubated for 3h at 371C, 5% CO2. The media were removed and
the formazan crystals formed in the viable cells were solubilised in
200ml DMSO. The absorbances at 540 and 690nm were determined
using a Titertek Multiscan ELISA plate reader and growth
inhibition calculated as a percentage of the A540–A690 of untreated
wells.
Animal studies
Male nude mice (O/Nu: outbred ALPK Nu/Nu) were purchased
from Zeneca (Macclesfield, UK). Animals were housed in a sterile
environment and allowed free access to food and water. MCF-7
human breast tumour xenograft samples (1–2mm
3) were
implanted in the right flank while the mice were under ethrane
and halothane anaesthesia and the experiments begun when
tumour volumes had reached a suitable size (see below). As MCF-7
tumours are oestrogen receptor positive, they required additional
oestrogen for growth. To prepare oestrogen pellets, b-oestradiol
(468mg) was added to 9.7g silastic and mixed. Curing agent (1.1g)
was added and the mixture spread into three
(26mm 12mm 1mm) glass formers. These were then incu-
bated at 421C overnight before being cut into
2mm 2mm 1mm cubes (B2mg oestradiol per pellet). The
pellets were stored at 41C until insertion subcutaneously at the tail
base, simultaneously with the tumour implant and monthly
thereafter. Agents were injected i.p. within 15min of preparation:
Temozolomide was injected 1h after PaTrin-2 or the vehicle
control. Animals were cared for in accordance with Home Office
guidelines
To measure MGMT depletion following PaTrin-2, six groups of
mice with at least five mice in each group received PaTrin-2
20mgkg
 1i.p. as a single dose. At varying times after dosing,
animals were terminated by cervical dislocation, and the tissues
(xenograft, kidneys, liver and lungs) dissected out and immedi-
ately frozen in dry ice. Bone marrow was collected from femora,
which were dissected from each mouse. A minimum amount of
bone was trimmed from each end and a 21-gauge needle inserted
through the epiphyseal cartilage and the bone marrow flushed into
an appropriate volume of PBS. Tissue was stored at  701C until
assayed for MGMT activity.
To assess the ability of PaTrin-2 to sensitise human breast
tumour xenografts to the tumour growth inhibitory effects of
temozolomide, groups of at least six nude mice were treated as
follows: the vehicle control group were given corn oil then 20%
DMSO in PBS; the temozolomide only group were given corn oil
then temozolomide (100mgkg
 1day
 1); the PaTrin-2 only group
were given PaTrin-2 (20mgkg
 1day
 1) then DMSO in PBS, and
the PaTrin-2 plus temozolomide group were given PaTrin-2
(20mgkg
 1day
 1) then temozolomide (100mgkg
 1day
 1). Drugs
or vehicles were administered i.p. once daily for 5 days with a
separation of 1h. Up to 10 and at least six animals were assigned to
each group, and mean tumour volume was standardised across the
groups at the start of the experiment: thus the control, PaTrin-2,
temozolomide and PaTrin-2 plus temozolomide groups had mean
tumour volumes of 29.877.6 (range 19.0–38.7), 33.2714.7 (range
16.5–58.7), 35.1710.9 (range 20.9–52.4) and 30.3710.0 (range
20.7–44.5)mm
3, respectively.
In all the tumour growth delay experiments, animal weights and
tumour volumes were measured twice per week. Tumour volumes
were calculated using the formula (length height width P/6)
with measurements taken using digital calipers.
The relative tumour volumes were plotted for each animal and
tumour quintupling times (tqt) determined. The statistical
significance of differences between treatment groups was evaluated
using the Mann–Whitney test. The maximum relative weight
losses observed in each group were compared using the Kruskal–
Wallis test.
RESULTS
Effect of PaTrin-2 on MGMT activity and temozolomide
sensitivity in MCF-7 cells
MCF-7 cells expressed high levels of MGMT (B1540fmolesmg
 1
total protein). Exposure to PaTrin-2 for 2h resulted in extensive
inactivation of MGMT in MCF-7 cells: the concentration required
to inactivate 50% of the MGMT was around 6nM (Figure 1).
The sensitivity of the MCF-7 cells to the growth inhibitory
effects of temozolomide was substantially increased by PaTrin-2.
Growth amounting to 60% of control was seen after 400mM
temozolomide alone but following preincubation with 10mM
PaTrin-2, 60% growth occurred at 10mM temozolomide (Figure 2),
indicating a 40-fold increase in sensitivity. PaTrin-2 itself had no
growth inhibitory effect.
Effect of PaTrin-2 on MGMT activity in host tissues and
tumour
Extensive depletion of MGMT activity was seen in all host tissues
measured after a single i.p. dose of 20mgkg
 1 PaTrin-2 (Figure 3).
Depletion to below the limits of detection occurred in the kidney,
while it was to B20, B35 and B40% of pretreatment values in
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sliver, lung and bone marrow, respectively. The nadir was generally
between 2 and 8h and substantial activity (to over 50% of
pretreatment levels) had returned by 24h after dosing. In the MCF-
7 xenografts, complete MGMT inactivation was seen between 2 and
8h, and recovery of levels was only to B20% of pretreatment levels
by 24h after dosing. Slower recovery in the xenograft might reflect
the relative strength of the human MGMT promoter or that the
human protein is more extensively inactivated by PaTrin-2 or its
putative metabolites.
Effect of PaTrin-2 and temozolomide on MCF-7 tumour
growth
The median MCF-7 tqt in the vehicle control and PaTrin-2 only
groups were B21 and B17 days, respectively. Neither temozolo-
mide (tqtB17 days) nor PaTrin-2 alone had any significant effect
on xenograft growth. However, the combination of PaTrin-2 and
temozolomide resulted in a median tumour quintupling time of
B43 days representing an increase of B22 days (Po0.005;
Figure 4, Table 1). Toxicity, as measured by weight loss, was
essentially unaffected by the addition of PaTrin-2 to the
temozolomide treatment regimen. At the end of the treatment
period, weight loss was B5% in both the temozolomide alone and
combination groups (Figure 5, Table 1).
DISCUSSION
The O
6-alkylating agent, temozolomide has been approved for the
treatment of malignant glioma and is under consideration for use
in melanoma, for which it is extensively prescribed, off license (e.g.
Kiebert et al, 2003). It has also been tested in patients with
metastatic breast cancer (NCIC, 2001) and prostate cancer (van
Brussel et al, 2000) but inherent drug resistance has resulted in no
clinical benefit. Several groups have measured MGMT expression
in human breast tumours and report activity that is low (Cao et al,
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Figure 1 Effect of PaTrin-2 on MGMT activity in MCF7 cells. Values
shown are determined from the slope of the activity assay curves and are
effectively the mean of at least triplicate estimations. See text for
experimental details.
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Figure 2 Effect of PaTrin-2 (10mM) on the sensitivity of MCF7 cells to
the growth inhibitory effects of temozolomide. See text for experimental
details.
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Figure 3 Kinetics of MGMT depletion in MCF-7 xenografts and other
tissues after a single intraperitoneal dose of PaTrin-2 (20mgkg
 1). Points
are the means of values (7error (s.d.) for tumour, liver, and kidney) from
at least five mice. In order to have sufficient material for assay, bone
marrow was pooled from five mice (no s.d. is shown). See text for
experimental details.
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Figure 4 Growth of MCF-7 tumour xenografts in nude mice. Treatment
was once daily for 5 days. Points are the means (7s.e.m.) of values from at
least five mice. See text for experimental details. Tz¼temozolomide.
Table 1 Effect of temozolomide7PaTrin-2 on human breast MCF-7
xenograft growth and animal weight
Treatment
group Growth delay (days)
a
Weight loss at end of
treatment (%)
Vehicles 0 1.2
PaTrin-2  3N D
Temozolomide  3.3 4.7
Both drugs 29.4
b,c 4.8
aTumour growth delay is the difference between the median time for tumours in
treated or control animals to quintuple in size (tumour quintupling time: tqt in text)
relative to the vehicle control.
bP¼0.005 compared to PaTrin-2 alone by Mann–
Whitney test.
cP¼0.003 compared to temozolomide alone by Mann–Whitney test.
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s1991), moderate (Chen et al, 1992) or high (Musarrat et al, 1995).
High levels of MGMT expression in the primary tumour have been
correlated with a poor prognosis in early breast cancer,
irrespective of the treatment regimen (Citron et al, 1994). We
have previously reported almost uniformly high levels of MGMT in
breast tumours as determined by functional assay and immuno-
histochemical analysis (Clemons et al, 2002). It seems reasonable
to suggest that resistance to temozolomde was mediated by these
high levels of expression of MGMT.
While the O
6-alkylating agents are currently not as widely used
in the management of breast cancer as they are in glioma,
malignant melanoma and lymphoma, the possibility of over-
coming alkylating agent resistance would make these agents useful
additions to the chemotherapeutic management of this much more
common malignancy. Attempts to improve the effectiveness of O
6-
alkylating agents therapy by prior inactivation of MGMT using
methylating agents have foundered owing to the similar, and hence
cumulative, toxicities of the inactivating and treatment drugs (Lee
et al, 1993; Smith et al, 1996; Clemons et al, 2002; Hammond et al,
2004).
Strategies have therefore focussed on the use of nontoxic MGMT
inactivators and it has been shown that O
6-BeG and PaTrin-2,
which very effectively inactivate MGMT in cells and tumours,
improve the therapeutic effect of alkylating agents in a number of
tumour models (Dolan and Pegg, 1997; Wedge et al, 1997;
Middleton et al, 2002). Phase I clinical trials of O
6-BeG in
combination with BCNU have shown increased myelosuppression,
requiring reduced doses for phase II studies (Spiro et al, 1999;
Schilsky et al, 2000; Friedman et al, 2000). Indeed, Chinnasamy
et al (1997) found that O
6-BeG pretreatment of mice significantly
increased the in vivo cytotoxicity and clastogenic effects of BCNU
in bone marrow. It has also been shown that the granulocyte–
macrophage precursor cells of primary human bone marrow
samples are dramatically sensitised to the toxic effects of
temozolomide by pre-exposure to O
6-BeG (Fairbairn et al, 1995;
Clemons et al, 2000). So far, phase II clinical trials have yet to
demonstrate that O
6-BeG provides an increase in therapeutic
index, that is, that the improvement in efficacy outweighs any
additional toxicity (Quinn et al, 2002).
PaTrin-2 is a more potent MGMT inactivator in vitro than O
6-
BeG, and we considered it worthwhile to examine the extent to
which PaTrin-2 could inactivate MGMT and increase sensitivity to
temozolomide in a human breast tumour model as a prerequisite
for any potential clinical trial in breast cancer. Our results show
that PaTrin-2 is also a potent inactivator of MGMT in MCF-7 cells
both in culture and in xenografts in vivo. Tumour MGMT
depletion by PaTrin-2 was as extensive as was reported with O
6-
BeG in other tumour types (see Dolan and Pegg, 1997). We also
showed that MGMT was inactivated in all host tissues with
complete inactivation in kidney and extensive inactivation in other
tissues. This collateral depletion again raises the concern about the
potentiation of toxicity in healthy tissues following PaTrin-2/
alkylating agent combinations.
The MGMT inactivation by PaTrin-2 in MCF-7 cells resulted in
marked sensitisation to temozolomide growth inhibition. Follow-
ing implantation into immune deficient mice, the resulting
xenografts are completely resistant to growth inhibition by a 5-
day treatment regimen using temozolomide alone. This was
probably a result of the resistance conferred by high levels of
expression of MGMT. PaTrin-2 alone had, as anticipated, no effect
on tumour growth rates. However, PaTrin-2 overcame the
resistance to temozolomide producing highly significant tumour
growth delays, but without increasing toxicity as judged by animal
weights. Thus, the therapeutic index of temozolomide is increased
by PaTrin-2 in this animal model. We have previously shown that
human melanoma xenografts expressing moderate levels of MGMT
do respond to growth inhibition by temozolomide, but this is
considerably enhanced by pretreatment with PaTrin-2 (Middleton
et al, 2000, 2002). Current phase I studies are investigating the dose
of PaTrin-2 that is necessary for complete inactivation of MGMT in
patients with a variety of cancer types, prior to phase II studies.
Given the results of the xenograft studies with melanoma, and
now breast cancer, it seems reasonable to speculate that the
greatest benefit from PaTrin-2-mediated inactivation of MGMT
might be seen in tumours with the highest levels of MGMT
expression and inherent resistance to temozolomide. This might
best be assessed in a phase II clinical trial in breast cancer,
particularly since temozolomide alone has been shown to be
ineffective in the MCIC trial. However, given the variable levels of
expression of MGMT in this tumour type, it would be beneficial to
assess MGMT levels in tumour biopsies from all patients in such a
study so that the hypothesis that MGMT inactivation will be
beneficial can be effectively tested.
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